Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals.

Research & information: general --- Chemistry --- positron emission tomography (PET) --- pyrazoles --- fluorine-18 --- radionuclides --- PET probes --- imaging pharmaceuticals --- hypopharyngeal cancer --- 188Re-liposome --- repeated therapy --- NGS --- microRNA --- aprepitant --- radiopharmaceuticals --- neurokinin 1 receptor antagonist --- radionuclide chelators --- kidney uptake --- cleavable linkers --- neutral endopeptidase (NEP) --- renal brush border enzymes --- prostate-specific membrane antigen (PSMA) --- cancer imaging and therapy --- somatostatin analogs --- radiolabeling --- radionuclide therapy --- imaging --- adrenergic receptor --- positron emission tomography --- radiotracer --- cholecystokinin-2 receptor --- minigastrin --- molecular imaging --- targeted radiotherapy --- lutetium-177 --- EpCAM --- radionuclide --- SPECT --- iodine --- PIB --- breast --- cancer --- PET --- target-specific biomolecules --- immunoPET imaging pharmaceuticals --- production processes --- 124I-labeled monoclonal antibodies --- radiotracers --- AAZTA --- scandium-44 --- FAP --- SA --- DPP --- PREP --- radioiodine labeling --- radioiodination --- biomolecules --- peptides --- proteins --- monoclonal antibodies --- 123,124,125,131I-labeled molecules and biomolecules --- positron emission tomography (PET) --- pyrazoles --- fluorine-18 --- radionuclides --- PET probes --- imaging pharmaceuticals --- hypopharyngeal cancer --- 188Re-liposome --- repeated therapy --- NGS --- microRNA --- aprepitant --- radiopharmaceuticals --- neurokinin 1 receptor antagonist --- radionuclide chelators --- kidney uptake --- cleavable linkers --- neutral endopeptidase (NEP) --- renal brush border enzymes --- prostate-specific membrane antigen (PSMA) --- cancer imaging and therapy --- somatostatin analogs --- radiolabeling --- radionuclide therapy --- imaging --- adrenergic receptor --- positron emission tomography --- radiotracer --- cholecystokinin-2 receptor --- minigastrin --- molecular imaging --- targeted radiotherapy --- lutetium-177 --- EpCAM --- radionuclide --- SPECT --- iodine --- PIB --- breast --- cancer --- PET --- target-specific biomolecules --- immunoPET imaging pharmaceuticals --- production processes --- 124I-labeled monoclonal antibodies --- radiotracers --- AAZTA --- scandium-44 --- FAP --- SA --- DPP --- PREP --- radioiodine labeling --- radioiodination --- biomolecules --- peptides --- proteins --- monoclonal antibodies --- 123,124,125,131I-labeled molecules and biomolecules

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals.

Research & information: general --- Chemistry --- positron emission tomography (PET) --- pyrazoles --- fluorine-18 --- radionuclides --- PET probes --- imaging pharmaceuticals --- hypopharyngeal cancer --- 188Re-liposome --- repeated therapy --- NGS --- microRNA --- aprepitant --- radiopharmaceuticals --- neurokinin 1 receptor antagonist --- radionuclide chelators --- kidney uptake --- cleavable linkers --- neutral endopeptidase (NEP) --- renal brush border enzymes --- prostate-specific membrane antigen (PSMA) --- cancer imaging and therapy --- somatostatin analogs --- radiolabeling --- radionuclide therapy --- imaging --- adrenergic receptor --- positron emission tomography --- radiotracer --- cholecystokinin-2 receptor --- minigastrin --- molecular imaging --- targeted radiotherapy --- lutetium-177 --- EpCAM --- radionuclide --- SPECT --- iodine --- PIB --- breast --- cancer --- PET --- target-specific biomolecules --- immunoPET imaging pharmaceuticals --- production processes --- 124I-labeled monoclonal antibodies --- radiotracers --- AAZTA --- scandium-44 --- FAP --- SA --- DPP --- PREP --- radioiodine labeling --- radioiodination --- biomolecules --- peptides --- proteins --- monoclonal antibodies --- 123,124,125,131I-labeled molecules and biomolecules --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Radiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals.

positron emission tomography (PET) --- pyrazoles --- fluorine-18 --- radionuclides --- PET probes --- imaging pharmaceuticals --- hypopharyngeal cancer --- 188Re-liposome --- repeated therapy --- NGS --- microRNA --- aprepitant --- radiopharmaceuticals --- neurokinin 1 receptor antagonist --- radionuclide chelators --- kidney uptake --- cleavable linkers --- neutral endopeptidase (NEP) --- renal brush border enzymes --- prostate-specific membrane antigen (PSMA) --- cancer imaging and therapy --- somatostatin analogs --- radiolabeling --- radionuclide therapy --- imaging --- adrenergic receptor --- positron emission tomography --- radiotracer --- cholecystokinin-2 receptor --- minigastrin --- molecular imaging --- targeted radiotherapy --- lutetium-177 --- EpCAM --- radionuclide --- SPECT --- iodine --- PIB --- breast --- cancer --- PET --- target-specific biomolecules --- immunoPET imaging pharmaceuticals --- production processes --- 124I-labeled monoclonal antibodies --- radiotracers --- AAZTA --- scandium-44 --- FAP --- SA --- DPP --- PREP --- radioiodine labeling --- radioiodination --- biomolecules --- peptides --- proteins --- monoclonal antibodies --- 123,124,125,131I-labeled molecules and biomolecules --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The issue of Cancers Journal entitled “Role of Medical Imaging in Cancers” presents a detailed summary of evidences about molecular imaging, including the role of computed tomography (CT), magnetic resonance imaging (MRI), single photon emission tomography (SPET) and positron emission tomography (PET) or PET/CT or PET/MR imaging in many type of tumors (i.e. sarcoma, prostate, breast and others), motivating the role of these imaging modalities in different setting of disease and showing the recent developments, in terms of radiopharmaceuticals, software and artificial intelligence in this field. The collection of articles is very useful for many specialists, because it has been conceived for a multidisciplinary point of view, in order to drive to a personalized medicine.

Medicine. --- positron emission tomography --- head and neck neoplasms --- neovascularization --- pathologic --- PET/CT --- urothelial carcinoma --- bladder cancer --- upper tract urothelial carcinoma --- survival --- PET --- PSMA --- prostate --- DCFPyL --- DCFBC --- PSMA-1007 --- ovarian cancer --- relapse --- SUVmax --- targeted therapy --- prognosis --- soft tissue sarcoma (STS) --- pazopanib --- dynamic 18F-FDG PET/CT --- SUV --- two-tissue compartment model --- magnetic resonance imaging --- machine learning --- diffusion --- perfusion --- texture analysis --- squamous cell carcinoma of the head and neck --- diffusion-weighted imaging --- malignant pleural mesothelioma --- pleural dissemination --- empyema --- pleural effusion --- mCRPC --- SPECT/CT --- Computer-assisted diagnosis --- XOFIGO --- Therapy response assessment --- circulating miRNAs --- breast cancer --- imaging parameters --- PET/MRI --- biomarkers --- triple negative breast cancer --- VCAM-1 --- SPECT imaging --- sdAbs --- Hounsfield unit --- computed tomography --- adipose tissue --- precision oncology --- FDG-PET/CT --- PERCIST --- metastatic breast cancer --- prostate cancer --- 18F-FACBC --- recurrence --- meta-analysis --- review --- meningioma --- somatostatin receptor --- neuroimaging --- radionuclide therapy --- breast --- imaging --- marker --- radiomics --- Yin Yang 1 --- PDAC --- Mesothelin --- noninvasive imaging --- receptor status --- molecular imaging --- nuclear medicine --- guidelines --- overutilization --- epistemology --- consensus --- mantle cell lymphoma --- 18F-FDG PET/CT --- Deauville criteria --- Radium-223 --- FDG --- castrate resistant prostate cancer --- programmed cell death 1 receptor --- diagnostic imaging --- CTLA-4 Antigen --- Immunotherapy --- Adoptive --- radioactive tracers --- radionuclide imaging --- CD8-Positive T-Lymphocytes --- PI-RADS --- diffusion kurtosis imaging --- dynamic contrast-enhanced magnetic resonance imaging --- 68Gallium-PSMA PET/CT --- prostate-specific-antigen --- PSA kinetics thresholds --- biochemical recurrence --- optimal cutoff level --- non-small-cell lung cancer --- circulating tumor cells --- immunotherapy --- response to treatment --- head and neck cancer --- HPV --- EBV --- p16 --- Molecular imaging --- miRNA expression --- radiogenomics --- radiomic --- diagnosis --- biomarker --- glioblastoma --- radiation therapy --- MRI --- diffusion tensor imaging --- Hodgkin lymphoma --- diffuse large B-cell lymphoma --- staging --- response assessment --- locally advanced cervical cancer --- concurrent chemoradiotherapy --- treatment response --- follow up --- cystic tumor --- International Consensus Guidelines --- intraductal papillary mucinous neoplasms --- pancreatic neoplasms --- PD-1 --- PD-L1 --- response to therapy --- NSCLC --- positron-emission tomography --- single-photon emission computed tomography --- immune checkpoint inhibitors --- gold nanoparticle --- heat shock protein 70 --- spectral-CT --- positron emission tomography --- head and neck neoplasms --- neovascularization --- pathologic --- PET/CT --- urothelial carcinoma --- bladder cancer --- upper tract urothelial carcinoma --- survival --- PET --- PSMA --- prostate --- DCFPyL --- DCFBC --- PSMA-1007 --- ovarian cancer --- relapse --- SUVmax --- targeted therapy --- prognosis --- soft tissue sarcoma (STS) --- pazopanib --- dynamic 18F-FDG PET/CT --- SUV --- two-tissue compartment model --- magnetic resonance imaging --- machine learning --- diffusion --- perfusion --- texture analysis --- squamous cell carcinoma of the head and neck --- diffusion-weighted imaging --- malignant pleural mesothelioma --- pleural dissemination --- empyema --- pleural effusion --- mCRPC --- SPECT/CT --- Computer-assisted diagnosis --- XOFIGO --- Therapy response assessment --- circulating miRNAs --- breast cancer --- imaging parameters --- PET/MRI --- biomarkers --- triple negative breast cancer --- VCAM-1 --- SPECT imaging --- sdAbs --- Hounsfield unit --- computed tomography --- adipose tissue --- precision oncology --- FDG-PET/CT --- PERCIST --- metastatic breast cancer --- prostate cancer --- 18F-FACBC --- recurrence --- meta-analysis --- review --- meningioma --- somatostatin receptor --- neuroimaging --- radionuclide therapy --- breast --- imaging --- marker --- radiomics --- Yin Yang 1 --- PDAC --- Mesothelin --- noninvasive imaging --- receptor status --- molecular imaging --- nuclear medicine --- guidelines --- overutilization --- epistemology --- consensus --- mantle cell lymphoma --- 18F-FDG PET/CT --- Deauville criteria --- Radium-223 --- FDG --- castrate resistant prostate cancer --- programmed cell death 1 receptor --- diagnostic imaging --- CTLA-4 Antigen --- Immunotherapy --- Adoptive --- radioactive tracers --- radionuclide imaging --- CD8-Positive T-Lymphocytes --- PI-RADS --- diffusion kurtosis imaging --- dynamic contrast-enhanced magnetic resonance imaging --- 68Gallium-PSMA PET/CT --- prostate-specific-antigen --- PSA kinetics thresholds --- biochemical recurrence --- optimal cutoff level --- non-small-cell lung cancer --- circulating tumor cells --- immunotherapy --- response to treatment --- head and neck cancer --- HPV --- EBV --- p16 --- Molecular imaging --- miRNA expression --- radiogenomics --- radiomic --- diagnosis --- biomarker --- glioblastoma --- radiation therapy --- MRI --- diffusion tensor imaging --- Hodgkin lymphoma --- diffuse large B-cell lymphoma --- staging --- response assessment --- locally advanced cervical cancer --- concurrent chemoradiotherapy --- treatment response --- follow up --- cystic tumor --- International Consensus Guidelines --- intraductal papillary mucinous neoplasms --- pancreatic neoplasms --- PD-1 --- PD-L1 --- response to therapy --- NSCLC --- positron-emission tomography --- single-photon emission computed tomography --- immune checkpoint inhibitors --- gold nanoparticle --- heat shock protein 70 --- spectral-CT

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

undefined

Medicine. --- positron emission tomography --- head and neck neoplasms --- neovascularization --- pathologic --- PET/CT --- urothelial carcinoma --- bladder cancer --- upper tract urothelial carcinoma --- survival --- PET --- PSMA --- prostate --- DCFPyL --- DCFBC --- PSMA-1007 --- ovarian cancer --- relapse --- SUVmax --- targeted therapy --- prognosis --- soft tissue sarcoma (STS) --- pazopanib --- dynamic 18F-FDG PET/CT --- SUV --- two-tissue compartment model --- magnetic resonance imaging --- machine learning --- diffusion --- perfusion --- texture analysis --- squamous cell carcinoma of the head and neck --- diffusion-weighted imaging --- malignant pleural mesothelioma --- pleural dissemination --- empyema --- pleural effusion --- mCRPC --- SPECT/CT --- Computer-assisted diagnosis --- XOFIGO --- Therapy response assessment --- circulating miRNAs --- breast cancer --- imaging parameters --- PET/MRI --- biomarkers --- triple negative breast cancer --- VCAM-1 --- SPECT imaging --- sdAbs --- Hounsfield unit --- computed tomography --- adipose tissue --- precision oncology --- FDG-PET/CT --- PERCIST --- metastatic breast cancer --- prostate cancer --- 18F-FACBC --- recurrence --- meta-analysis --- review --- meningioma --- somatostatin receptor --- neuroimaging --- radionuclide therapy --- breast --- imaging --- marker --- radiomics --- Yin Yang 1 --- PDAC --- Mesothelin --- noninvasive imaging --- receptor status --- molecular imaging --- nuclear medicine --- guidelines --- overutilization --- epistemology --- consensus --- mantle cell lymphoma --- 18F-FDG PET/CT --- Deauville criteria --- Radium-223 --- FDG --- castrate resistant prostate cancer --- programmed cell death 1 receptor --- diagnostic imaging --- CTLA-4 Antigen --- Immunotherapy --- Adoptive --- radioactive tracers --- radionuclide imaging --- CD8-Positive T-Lymphocytes --- PI-RADS --- diffusion kurtosis imaging --- dynamic contrast-enhanced magnetic resonance imaging --- 68Gallium-PSMA PET/CT --- prostate-specific-antigen --- PSA kinetics thresholds --- biochemical recurrence --- optimal cutoff level --- non-small-cell lung cancer --- circulating tumor cells --- immunotherapy --- response to treatment --- head and neck cancer --- HPV --- EBV --- p16 --- Molecular imaging --- miRNA expression --- radiogenomics --- radiomic --- diagnosis --- biomarker --- glioblastoma --- radiation therapy --- MRI --- diffusion tensor imaging --- Hodgkin lymphoma --- diffuse large B-cell lymphoma --- staging --- response assessment --- locally advanced cervical cancer --- concurrent chemoradiotherapy --- treatment response --- follow up --- cystic tumor --- International Consensus Guidelines --- intraductal papillary mucinous neoplasms --- pancreatic neoplasms --- PD-1 --- PD-L1 --- response to therapy --- NSCLC --- positron-emission tomography --- single-photon emission computed tomography --- immune checkpoint inhibitors --- gold nanoparticle --- heat shock protein 70 --- spectral-CT --- n/a